Dr. Kathrin Strasser-Weippl
Strasser-Weippl, K, Ludwig, H. (2008): Psychosocial QOL is an independent predictor of overall survival in newly diagnosed patients with multiple myeloma. Eur J Haematol 81(5):374-379.
Heintel, D, Zojer, N, Schreder, M, Strasser-Weippl, K, Kainz, B, Vesely, M, Gisslinger, H, Drach, J, Gaiger, A, Jäger, U, Ludwig, H (2008) Expression of MUM1/IRF4 mRNA as a prognostic marker in patients with multiple myeloma. Leukemia. Feb;22(2):441-5
Strasser-Weippl, K, Ludwig, H (2007): A survey among oncologists on measures needed to improve cancer care. Onkologie 2007 Jul;30(7):367-72
Steurer, M, Zoller, H, Augustin, F, Fong, D, Heiss, S, Strasser-Weippl, K, Gastl, G, Tzankov, A: (2007): Increased angiogenesis in chronic idiopathic myelofibrosis: vascular endothelial growth factor as a prominent angiogenic factor. Hum Pathol 38(7):1057-64
Goss, PE, Strasser-Weippl, K, Qi, S, Hu, H: (2007) Effects of liarozole fumarate (R85246) in combination with tamoxifen on N-methyl-N-nitrosourea (MNU)-induced mammary carcinoma and uterus in the rat model. BMC Cancer 7:26.
Strasser-Weippl, K, Steurer M, Kees, M, Augustin, F, Tzankov, A, Dirnhofer, S, Fiegl, M, Zojer, N, Gisslinger, H, Ludwig, H: (2006): Prognostic Relevance of cytogenetics determined by FISH in patients with myelofibrosis with myeloid metaplasia. Cancer 107 (12):2801-6.
Strasser-Weippl, K, Steurer M, Kees, M, Augustin, F, Tzankov, A, Dirnhofer, S, Fiegl, M, Simonitsch-Klupp, I, Zojer, N, Gisslinger, H, Ludwig, H: (2006): Age and hemoglobin level emerge as most important clinical prognostic parameters in patients with osteomyelofibrosis: introduction of a simplified prognostic score. Leuk Lymphoma 47 (3):441-450
Strasser-Weippl, K., Steurer, M., Kees, M., Augustin, F., Tzankov, A., Dirnhofer, S., Fiegl, M., Gisslinger, H., Zojer, N., Ludwig H. (2005) Chromosome 7 deletions are associated with unfavorable prognosis in myelofibrosis with myeloid metaplasia. Blood 105, 4146.
Thompson, L.U., Chen, J.M., Li, T., Strasser-Weippl, K., Goss, P.E.: (2005): Dietary flaxseed reduced tumor growth in postmenopausal patients with breast cancer. Clin Cancer Res 11(10):3828-35
Strasser, K., Ludwig, H. (2002) Thalidomide treatment in multiple myeloma. Blood Reviews 16, pp. 207-213
Goss, P.E., Strasser, K. (2002) Tamoxifen resistant and refractory breast cancer: the value of aromatase inhibitors. Drugs, 62, pp.957-966
Zojer, N., Schuster-Kolbe, J., Assmann, I., Ackermann, J., Strasser, K., Hübl, W., Drach, J., Ludwig, H. (2002) Chromosomal aberrations are shared by malignant plasma cells and a small fraction of circulating CD19+ cells in patients with myeloma and monoclonal gammopathy of undetermined significance. Br J Haematol 117, pp. 852-859
Goss, P.E., Strasser, K. (2001): Aromatase Inhibitors in the Treatment and Prevention of Breast Cancer. J Clin Oncol 19, pp. 881-894
Strasser, K., Zojer, N., Fiegl, M., Steurer, M., Dirnhofer, S., Assmann, I., Ludwig, H. (2001) Cytogenetic aberrations can be found in patients with primary osteomyelofibrosis. Proceedings of the Conference of the German and Austrian Societies of Hematology and Oncology, Mannheim (abstr)
Goss, P.E., Strasser, K., Marques, R. et al (2000) Liarozole fumarate (R85246): In the treatment of ER negative, tamoxifen refractory or chemotherapy resistant postmenopausal metastatic breast cancer. Breast Cancer Res Treat 64, pp. 177-88
Strasser, K., Goss, P.E., Tye, L.M. (2000) Effects of liarozole fumarate (R85246) in combination with tamoxifen. Proc Am Soc Clin Oncol (abstr)
Strasser, K., Leitgeb, C., Boogaerts, M., Harrousseau, J.L., Ludwig, H. (2001) IL-4 treatment in patients with multiple myeloma relapsing or refractory to previous chemotherapy. International Myeloma Workshop, Banff, Canada (abstr)
Goss, P.E., Strasser, K. (2002) Chemoprevention with aromatase inhibitors – trial strategies. J Steroid Biochem Mol Biol, 79, pp.143-149